^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jemperli (dostarlimab-gxly)

    i
    Other names: TSR-042, ANB011, GSK4057190, ANB 011, WBP-285, TSR 042, TSR042, ANB-011, GSK-4057190, GSK 4057190, WBP 285, WBP285
    Company:
    AnaptysBio, GSK, Sagard Healthcare
    Drug class:
    PD1 inhibitor
    Related drugs:
    3d
    NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
    P2, N=51, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Dec 2027 --> Feb 2025 | Suspended --> Terminated; Abandon of the partner, GSK
    Trial completion date • Trial termination • Pan tumor • Platinum sensitive
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    3d
    Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer patients: demystifying the 100% clinical complete response paradigm. (PubMed, Oncologist)
    shows a cCR rate of 100% that allowed sparing chemoradiation and surgery to all included patients. Here, we present three clinical cases of patients with dMMR and MSI-H LARC treated with neoadjuvant dostarlimab at three Italian institutions with radiological evidence of disease progression while on treatment and discuss potential similarities among them to understand when and how this apparently rare event may occur.
    Journal • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Jemperli (dostarlimab-gxly)
    17d
    China AZUR-1: A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting
    Enrollment closed • MSI-H • dMMR
    |
    Jemperli (dostarlimab-gxly)
    19d
    Mathematical model of optimal control for endometrial cancer with treatments dostarlimab and chemotherapy using Caputo derivative. (PubMed, Sci Rep)
    The [Formula: see text] model provides faster tumor reduction and higher immune activation, whereas the [Formula: see text] model achieves lower overall therapeutic cost by balancing tumor reduction with reduced drug usage. These findings highlight the potential of optimal control strategies particularly combined therapy for improving treatment outcomes in endometrial cancer management.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Jemperli (dostarlimab-gxly)
    22d
    A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer (clinicaltrials.gov)
    P1/2, N=83, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jan 2032 --> Oct 2026 | Trial primary completion date: Jan 2032 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    23d
    Immunotherapy in advanced endometrial cancer with microsatellite instability: A systematic review. (PubMed, Farm Hosp)
    The efficacy of pembrolizumab and pembrolizumab-lenvatinib regimen appears promising. However, studies with larger sample size, longer follow-up and comparative design with subgroup analysis based on differences in microsatellite repair mechanisms are needed for proper therapeutic positioning.
    Review • Journal • Microsatellite instability
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Imfinzi (durvalumab) • Lenvima (lenvatinib) • Bavencio (avelumab) • Imjudo (tremelimumab-actl) • Jemperli (dostarlimab-gxly)
    24d
    First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=158, Recruiting, GlaxoSmithKline | Trial completion date: Sep 2028 --> Aug 2027 | Trial primary completion date: Sep 2028 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • GSK5764227 • nelistotug (GSK6097608)
    28d
    DREAMM 5: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P2, N=208, Active, not recruiting, GlaxoSmithKline | Trial completion date: Feb 2029 --> Mar 2027 | Trial primary completion date: Feb 2029 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Jemperli (dostarlimab-gxly) • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat) • feladilimab (GSK3359609) • GSK3174998
    1m
    Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer. (PubMed, Gynecol Oncol)
    Personalized treatment strategies incorporating HER2 and MMR testing should be considered to optimize both cost-effectiveness and equity in care.
    Journal • HEOR • IO biomarker • Cost-effectiveness
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    MSI-H/dMMR
    |
    Herceptin (trastuzumab) • Jemperli (dostarlimab-gxly)
    1m
    GARNET: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=738, Active, not recruiting, Tesaro, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Jan 2027
    Enrollment closed • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    EGFR mutation • MSI-H/dMMR • ALK translocation
    |
    Jemperli (dostarlimab-gxly)
    1m
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=463, Active, not recruiting, Tesaro, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Mar 2027
    Enrollment closed • Trial primary completion date
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    1m
    Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=107, Active, not recruiting, GlaxoSmithKline | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • belrestotug (EOS-448) • nelistotug (GSK6097608)